{"id":1879,"date":"2025-06-19T09:18:32","date_gmt":"2025-06-19T09:18:32","guid":{"rendered":"https:\/\/endourolojibulteni.com\/en\/?p=1879"},"modified":"2025-06-19T09:18:33","modified_gmt":"2025-06-19T09:18:33","slug":"vol-17-issue-2","status":"publish","type":"post","link":"https:\/\/endourolojibulteni.com\/en\/vol-17-issue-2\/","title":{"rendered":"Vol 17 Issue 2"},"content":{"rendered":"\n

Editorial Board Message<\/h3>\n\n\n\n

Prof.Dr. R. G\u00f6khan ATI\u015e<\/p>\n\n\n

PDF<\/span><\/summary>
\n\n
\"\"<\/a><\/figure>\n\n<\/div><\/details><\/div>\n\n\n
\n\n\n\n

Editorial Borad<\/h3>\n\n\n
PDF<\/span><\/summary>
\n\n
\"\"<\/a><\/figure>\n\n<\/div><\/details><\/div>\n\n\n
\n\n\n\n

Arbitrators List<\/h3>\n\n\n
PDF<\/span><\/summary>
\n\n
\"\"<\/a><\/figure>\n\n<\/div><\/details><\/div>\n\n\n
\n\n\n\n

Contents<\/h3>\n\n\n
PDF<\/span><\/summary>
\n\n
\"\"<\/a><\/figure>\n\n<\/div><\/details><\/div>\n\n\n
\n\n\n\n

Original Article<\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/p>\n\n\n\n

Lower Cost Way of Retrograde Intrarenal Surgery<\/h3>\n\n\n\n

Aydemir Asdemir, Abuzer \u00d6zt\u00fcrk, \u0130smail Emre Ergin, H\u00fcseyin Sayg\u0131n, Esat Kor\u011fal\u0131<\/p>\n\n\n

Abstract<\/span><\/summary>
\n\n

Objective: <\/strong>The aim of this study is to compare the results of operations with re-use flexible ureterorenoscope (URS) (FLEX X2, Karl Storz ) and single-use digital URS (RP-U-C12, Redpine) and find lower cost way of retrograde intrarenal surgery (RIRS) without compromising their clinical performance.<\/p>\n\n\n\n

Material and Methods: <\/strong>One re-use URS and one single-use digital URS were investigated with respect to operation numbers, times, laser and fluoroscopy times in operations and their effectiveness in the operations. All operations were achieved by same surgeon who has completed RIRS learning curve. Two small groups of patients (n = 63 for each group) was taken because it can be reached by one re-use URS.<\/p>\n\n\n\n

Results: <\/strong>The clinical application of the single-use URS is of equal quality compared to re-use one. In our study one case with FLEX X2 costs 399 euros, one case with RP-U-C12 costs 51.5 euros (only ureterorenoscope and its sterilization costs). This shows us single-use URS is lower cost way of retrograde intrarenal surgery.<\/p>\n\n\n\n

Conclusion: <\/strong>Now for our country one FLEX X2 costs as same as 41 RP-U-C12. But if you use RP-U-C12 as re-use flexible URS as we do, for one case with FLEX X2 costs nearly 8 times with RP-U-C12 costs. This shows us that RP-U-C12 has much lower cost. Our clinical evaluation showed markedly high performance for the single-use ureterorenoscope, which is comparable to the one of multi-used instruments.<\/p>\n\n\n\n

Keywords: <\/strong>cost-effective, re-use, flexible ureterorenoscope<\/p>\n\n<\/div><\/details><\/div>\n\n

PDF<\/span><\/summary>
\n\n
\"\"<\/a><\/figure>\n\n<\/div><\/details><\/div>\n\n\n
\n\n\n\n

Original Article<\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/p>\n\n\n\n

How Reliable are Imaging Study Reports in Assessing Pediatric Ureteropelvic Junction Obstruction? A Real-World Experience<\/h3>\n\n\n\n

Ali Sezer, Emre Kandemir, Bilge T\u00fcredi<\/p>\n\n\n

Abstract<\/span><\/summary>
\n\n

Objective: <\/strong>Serial ultrasonography (US) and nuclear scintigraphy imaging are sufficient in the decision-making process in most ureteropelvic-juntion obstruction (UPJO) patients. Contrast-enhanced cross-sectional imaging (CE-CSI) can be used in uncertain indications or the presence of additional anatomical anomalies. We evaluate the effectiveness and reliability of pre-operative US and CE-CSI reports of UPJO patients who underwent pyeloplasty.<\/p>\n\n\n\n

Material and Methods:<\/strong> The data of pediatric patients under the age of 18 who underwent CE-CSI with suspicion of UPJO between March 2020-2024 and who subsequently underwent pyeloplasty were reviewed retrospectively. The patients were divided into two groups. Primarily, ultrasound and CE-CSI reports were compared, and secondarily, the initial and re-evaluated CE-CSI report findings were compared in terms of the reporting of crossing vessels (CV).<\/p>\n\n\n\n

Results: <\/strong>The data of 44 patients (23 boys and 21 girls) with a mean age of 8.1 years were reviewed. Ultrasound and CE-CSI reports were compared, and it was seen that significantly more parenchymal thickness information was reported in the CE-CSI group than in the US group (CE-CSI:31(70.5%), US:18(40.9%), p=0.007). Crossing vessels were reported in 10 patients (41.6%) in initial CE-CSI reports. After re-evaluation of images by a radiologist who cooperated with the pediatric urologist, CV was reported in 21 patients (87.5%), and the difference was statistically significant (p=0.003) <\/p>\n\n\n\n

Conclusion:<\/strong> Despite its disadvantages in the pediatric age group, the success of CE-CSI in revealing detailed anatomical information, particularly vascular anatomy, cannot be ignored. Our study demonstrated that investigating the presence of CV in pediatric patients with UPJO is crucial, particularly in older and symptomatic children. In CE-CSI, the results should be evaluated by an experienced uroradiologist.<\/p>\n\n\n\n

Keywords: <\/strong>cross-sectional imaging, pyeloplasty, ureteropelvic-junction obstruction, ultrasound<\/p>\n\n<\/div><\/details><\/div>\n\n

PDF<\/span><\/summary>
\n\n
\"\"<\/a><\/figure>\n\n<\/div><\/details><\/div>\n\n\n
\n\n\n\n

Original Article<\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/p>\n\n\n\n

Comparison of Pneumatic Lithotripter and Holmium-YAG Laser Lithotripter in Supine Mini Percutaneous Nephrolithotomy: A Single-Centre Experience<\/h3>\n\n\n\n

Cengiz \u00c7anakc\u0131, Orkunt \u00d6zkaptan, Erdin\u00e7 Din\u00e7er, Fatih B\u0131\u00e7akl\u0131o\u011flu, O\u011fuz T\u00fcrky\u0131lmaz, U\u011fur Y\u0131lmaz<\/p>\n\n\n

Abstract<\/span><\/summary>
\n\n

Objective: <\/strong>The aim of this study was to compare the efficacy and safety of lithotripters used in supine mini percutaneous nephrolithotomy.<\/p>\n\n\n\n

Material and Methods: <\/strong>Medical record of patients who underwent mini percutaneous nephrolithotomy in supine position between January 2023 and June 2024 due to kidney stone larger than 2 cm were evaluated. Thirty-nine patients were operated with Ho:YAG laser lithotripter (LL) and 54 patients were operated with pneumatic lithotripter (PL). Results of patients\u2019 demographics, stone size, stone density, operation time, stone-free rate (SFR), complications were compared.<\/p>\n\n\n\n

Results:<\/strong> Mean age was 49.56\u00b113.02 in LL group and 50.20\u00b114.24 in PL group (p=0.825). Mean stone size was 3184\u00b12117 mm\u00b3 in LL group and 4117\u00b12975 mm\u00b3 in PL group and the results were similar between groups (p=0.097). Operation time was significantly higher in LL group than PL group (99.8\u00b124.7 min, 85.7\u00b128.1 min, respectively). SFR at postoperative 3rd month was similar between groups (92% in LL, 87% in PL) (p=0.512). Hemoglobin decrease rate (1.5\u00b11.1 g\/dL (IQR 1.5 g\/dL) (LL) vs. 1.6\u00b11.0 g\/dL (IQR 1.6 g\/dL) (PL), p=0.513) and overall complication rates (20% vs. 18%, p=0.897, respectively) were similar in the groups.<\/p>\n\n\n\n

Conclusion: <\/strong>Both lithotripters can be preferred effectively in supine percutaneous lithotomy. Ballistic lithotripters are still a safe and effective option for mini-PNL with the advantage of reduced operation time.<\/p>\n\n\n\n

Keywords: <\/strong>kidney stone, lithotripsy, supine percutaneous nephrolithotomy, laser, pneumatic<\/p>\n\n<\/div><\/details><\/div>\n\n

PDF<\/span><\/summary>
\n\n
\"\"<\/a><\/figure>\n\n<\/div><\/details><\/div>\n\n\n
\n\n\n\n
\n

Original Article<\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/p>\n\n\n\n

The Long-Term Effects on Recurrence and Progression of Bladder Tumors of Chemotherapeutic Agents Used After Transurethral Resection<\/h3>\n\n\n\n

Emre K\u0131ra\u00e7, Esat Kor\u011fal\u0131, H\u00fcseyin Sayg\u0131n, Aydemir Asdemir, \u0130smail Emre Ergin,Abuzer \u00d6zt\u00fcrk, Arslan Fatih Velibeyo\u011flu, Adem K\u0131r<\/p>\n\n\n

Abstract<\/span><\/summary>
\n\n

Objective: <\/strong>Early single dose chemotherapy may have a reducing effect on recurrence and progression. In this study, we aimed to compare non-muscle invasive patients diagnosed with bladder cancer who did not receive early single dose chemotherapy and those who received intravesical Epirubicin or Gemcitabine in terms of recurrence and progression.<\/p>\n\n\n\n

Material and Methods:<\/strong> 116 patients were followed up for 48 months (May 2020-June 2022) with diagnosis of primary non-invasive bladder cancer. After transurethral resection of the bladder, patients were followed up with 3 groups: who received intravesical epirubicin, who received gemcitabine, who did not receive any chemotherapeutic agent. <\/p>\n\n\n\n

Results: <\/strong>The mean age was 63. There were no statistically significant difference in age and, body mass index. Recurrence was determined 57.1% (n=20), 40% (n=18), and 41.7% (n=15) (p=0.263) of the patients, respectively who were not administered any intravesical agent, were administered Epirubicin and, Gemcitabine. While recurrence rates were observed 50%, 25%, 0% (p=0.177) respectively, in low-risk, no progression was detected. In intermediate risk group, 66.7%, 33.3%, 42.8% (p=0.378) recurrence, and 33.3%, 22.7%, 6.7% (p=0.282) progression were detected, respectively. High-risk group, recurrence was found in 56%, 64.2%, 56.2% (p=0.866) of the patients and progression 8%, 14.3%, 6.3% (p=0.723) respectively. In low-grade group, 35.7%, 42.9%, 21.4% (p=0.045) recurrence, and 16.6%, 12.1%, and 4.3% (p=0.164) progression were determined , respectively. In the high-grade group, 58.8%, 50%, 69.2% (p=0.982) recurrence, 5.9%, 16.6% and 7.7% (p=0.581) progression were detected, respectively.<\/p>\n\n\n\n

Conclusion: <\/strong>These findings demonstrated that intravesical chemotherapeutics can delay or prevent recurrence and progression, should therefore be administered in early postoperative period. Gemcitabine is not in widespread use and has been found to be a good alternative.<\/p>\n\n\n\n

Keywords: <\/strong>bladder cancer, recurrence, progression, epirubicin, gemcitabine<\/p>\n\n<\/div><\/details><\/div>\n\n

PDF<\/span><\/summary>
\n\n
\"\"<\/a><\/figure>\n\n<\/div><\/details><\/div>\n\n\n
\n<\/div><\/div>\n\n\n\n
\n

Original Article<\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/p>\n\n\n\n

The Relationship Between Urinary System Stone Disease and Serum Fetuin-A Glycoprotein<\/h3>\n\n\n\n

Abdulmecit Yavuz, Serdar Ar\u0131san<\/p>\n\n\n

Abstract<\/span><\/summary>
\n\n

Objective: <\/strong>This study aimed to investigate the relationship between Fetuin-A glycoprotein, a known systemic and localized calcification inhibitor, and urinary system stone disease.\u00a0<\/p>\n\n\n\n

Material and Methods: <\/strong>A total of 63 patients with urinary stone disease and 70 healthy controls were included. Serum Fetuin-A levels were measured using enzyme-linked immunosorbent assay, and various biochemical parameters were analyzed. Statistical comparisons were performed by using Pearson correlation to determine relationships, with significance set at p<0.05.\u00a0 <\/p>\n\n\n\n

Results: <\/strong>The mean serum Fetuin-A levels were slightly higher in the stone disease group (503.5 \u00b1 87.6 mg\/dL) compared to the control group (462.7 \u00b1 101.6 mg\/dL); however, the difference was not statistically significant (p>0.05). The mean age was 42.87 \u00b1 11.0 years in the stone group and 41.6 \u00b1 11.7 years in the control group (p=0.497). In the stone group, 65% were male and 35% female, while in the control group, 66% were male and 34% female, with no significant difference in gender distribution (p=0.831). Body mass index (BMI) was 25.3 \u00b1 2.57 kg\/m\u00b2 in the stone group and 26.9 \u00b1 3.08 kg\/m\u00b2 in the control group, also showing no significant difference (p=0.067). No correlations were found between serum Fetuin-A levels and other parameters such as age, BMI, or biochemical markers.\u00a0 <\/p>\n\n\n\n

Conclusion: <\/strong>Although some previous studies have suggested a relationship between Fetuin-A levels and urinary stone disease, this study found no significant association. Further research focusing on genetic polymorphisms of Fetuin-A may clarify its role in stone formation.\u00a0<\/p>\n\n\n\n

Keywords: <\/strong>kidney calculi, urinary calculi, fetuins<\/p>\n\n<\/div><\/details><\/div>\n\n

PDF<\/span><\/summary>
\n\n
\"\"<\/a><\/figure>\n\n<\/div><\/details><\/div>\n\n\n
\n<\/div><\/div>\n\n\n\n
\n

Original Article<\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/p>\n\n\n\n

Comparison of Outcomes Between Disposable and Reusable Flexible Ureteroscopes in the Treatment of Lower Pole Renal Stones<\/h3>\n\n\n\n

Adem Tun\u00e7ekin, Arda Tongal S\u00fcleyman Sa\u011f\u0131r, Yasin Akta\u015f Erkan Arslan<\/p>\n\n\n

Abstract<\/span><\/summary>
\n\n

Objective: <\/strong>Kidney stone disease is a significant health problem that substantially affects individuals\u2019 quality of life. Approximately 30% of kidney stones are located in the lower pole, which presents challenges in accessing these stones during retrograde intrarenal surgery. In the surgical treatment of lower pole kidney stones, we aimed to evaluate the efficacy and success rates of single-use and reusable flexible ureterorenoscopes, and to determine the most optimal option based on these findings.<\/p>\n\n\n\n

Material and Methods: <\/strong>This study included patients with lower pole kidney stones who underwent retrograde intrarenal surgery. Patients were divided into two groups based on the type of ureterorenoscope used: single-use or reusable. The collected data were compared between the two groups.<\/p>\n\n\n\n

Results:<\/strong> A total of 61 patients, including 34 men and 27 women, were included in the study. Thirty-four patients were evaluated in the single-use group, and 27 patients in the reusable group. The median stone size was 78.5 mm\u00b2 (50.3\u2013127.6) mm\u00b2 in the reusable group and 125.3 mm\u00b2 (56.5\u2013201.1) mm\u00b2 in the single-use group. There was no statistically significant difference between the groups in terms of demographic characteristics, Clavien-Dindo scores, or postoperative complications (p > 0.05). However, vomiting was observed significantly less frequently in the single-use group compared to the reusable group (p < 0.05). <\/p>\n\n\n\n

Conclusion: <\/strong>Flexible ureterorenoscopes are commonly used in the surgical management of lower pole kidney stones. When choosing between single-use and reusable flexible ureterorenoscopes, factors such as cost and ease of use should be taken into consideration. To better compare the advantages of each type and obtain more reliable results, larger case series and prospective studies are needed.<\/p>\n\n\n\n

Keywords: <\/strong>ureteroscopes, urolithiasis, kidney stone<\/p>\n\n<\/div><\/details><\/div>\n\n

PDF<\/span><\/summary>
\n\n
\"\"<\/a><\/figure>\n\n<\/div><\/details><\/div>\n\n\n
\n<\/div><\/div>\n\n\n\n
\n

Original Article<\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/p>\n\n\n\n

Evaluation of the Effectiveness of Local Anesthesia and Patient Tolerance in Penile Prosthesis Implantation<\/h3>\n\n\n\n

Ali Erhan Eren, Baran Arslan, M\u00fccahit Gelmi\u015f, Mehmet Salih Bo\u011fa, Ekrem \u0130slamo\u011flu<\/p>\n\n\n

Abstract<\/span><\/summary>
\n\n

Objective:<\/strong> This study aims to evaluate the effectiveness, safety, and patient tolerance of penile prosthesis implantation (PPI) performed under local anesthesia (LA). The study investigates its impact on perioperative pain management, postoperative recovery, and overall patient satisfaction.<\/p>\n\n\n\n

Material and Methods:<\/strong> This prospective study included 26 male patients who underwent PPI under LA between January 2024 and December 2024. Ethical approval was obtained from the Ethics Committee Antalya Training and Research Hospital No: 2\/24, Date: 30.01.2025). Pain intensity was assessed using the Visual Analog Scale (VAS), while patient stability and intraoperative parameters were monitored. The American Society of Anesthesiologists (ASA) classification system was used for anesthesia risk assessment.<\/p>\n\n\n\n

Results:<\/strong> The mean age of the patients was 67.25 \u00b1 11.48 years. Diabetes mellitus and hypertension were present in 75% and 62.5% of patients, respectively. According to ASA classification, 46.2% were classified as ASA-II, while 53.8% were ASA-III. The mean intraoperative VAS score was 1.8 (mild pain), while the mean postoperative VAS score was 4.6 (mild-to-moderate pain). No patients required additional sedation or conversion to general anesthesia. No major intraoperative complications or postoperative prosthesis-related complications were observed.<\/p>\n\n\n\n

Conclusion: <\/strong>Local anesthesia is a feasible and effective alternative for penile prosthesis implantation, offering benefits such as minimal intraoperative discomfort, avoidance of systemic anesthetic complications, and a favorable recovery profile. Further studies with larger cohorts are needed to optimize pain management strategies and evaluate long-term functional outcomes.<\/p>\n\n\n\n

Keywords:<\/strong> penile prosthesis implantation, local anesthesia, erectile dysfunction, pain management<\/p>\n\n<\/div><\/details><\/div>\n\n

PDF<\/span><\/summary>
\n\n
\"\"<\/a><\/figure>\n\n<\/div><\/details><\/div>\n\n\n
\n<\/div><\/div>\n\n\n\n
\n

Case Report<\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/p>\n\n\n\n

Nephrostomy Tube Placed in the Vena Cava as a Complication of Percutaneous Nephrolithotomy: A Case Report<\/h3>\n\n\n\n

Abdullah G\u00f6lba\u015f\u0131, \u0130brahim Yay, Eren Cengiz, H\u00fcseyin Bi\u00e7er, Burak Elmaa\u011fa\u00e7, Onur Demirba\u015f, Mert Ali Karada\u011f<\/p>\n\n\n

Abstract<\/span><\/summary>
\n\n

Percutaneous nephrolithotomy (PNL) is an important approach for removing kidney stones. Percutaneous nephrostomy drainage tube placement is performed to prevent extravasation and ensure hemostasis after PNL surgery. In this case, we will report on the successful conservative removal of the nephrostomy tube extending into the inferior vena cava, which was inserted to provide hemostasis after unilateral PNL surgery. Sometimes, as in our case, the catheter may perforate the renal parenchyma and extend into the renal vein or even the vena cava. In our case, the nephrostomy tube was located in the inferior vena cava (IVC). In case of possible massive bleeding that we could not control, the catheter was removed under fluoroscopy in the presence of the Cardiovascular Surgery-Interventional Radiology team. The patient had no problems during follow-up and was discharged successfully.<\/p>\n\n\n\n

Keywords:<\/strong> percutaneous nephrolithotomy, renal stone, nephrostomy tube, inferior vena cava<\/p>\n\n<\/div><\/details><\/div>\n\n

PDF<\/span><\/summary>
\n\n
\"\"<\/a><\/figure>\n\n<\/div><\/details><\/div>\n\n\n
\n<\/div><\/div>\n\n\n\n
\n

Review<\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/em><\/strong><\/p>\n\n\n\n

Metaphlyxia in Urinary System Stone Disease<\/h3>\n\n\n\n

Nihat Karabacak, Ali Atan, Fazl\u0131 Polat<\/p>\n\n\n

Abstract<\/span><\/summary>
\n\n

<\/p>\n\n<\/div><\/details><\/div>\n\n

PDF<\/span><\/summary>
\n\n
\"\"<\/a><\/figure>\n\n<\/div><\/details><\/div>\n\n\n
\n<\/div><\/div>\n\n\n\n

Full Text<\/h4>\n\n\n
PDF<\/span><\/summary>
\n\n
\"\"<\/a><\/figure>\n\n<\/div><\/details><\/div>\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Editorial Board Message Prof.Dr. R. G\u00f6khan ATI\u015e Editorial Borad Arbitrators List Contents Original Article Lower Cost Way of<\/p>\n","protected":false},"author":1,"featured_media":1699,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6,2,8],"tags":[],"class_list":["post-1879","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-archive","category-endourology-bulletin","category-home-page"],"_links":{"self":[{"href":"https:\/\/endourolojibulteni.com\/en\/wp-json\/wp\/v2\/posts\/1879","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/endourolojibulteni.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/endourolojibulteni.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/endourolojibulteni.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/endourolojibulteni.com\/en\/wp-json\/wp\/v2\/comments?post=1879"}],"version-history":[{"count":22,"href":"https:\/\/endourolojibulteni.com\/en\/wp-json\/wp\/v2\/posts\/1879\/revisions"}],"predecessor-version":[{"id":1901,"href":"https:\/\/endourolojibulteni.com\/en\/wp-json\/wp\/v2\/posts\/1879\/revisions\/1901"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/endourolojibulteni.com\/en\/wp-json\/wp\/v2\/media\/1699"}],"wp:attachment":[{"href":"https:\/\/endourolojibulteni.com\/en\/wp-json\/wp\/v2\/media?parent=1879"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/endourolojibulteni.com\/en\/wp-json\/wp\/v2\/categories?post=1879"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/endourolojibulteni.com\/en\/wp-json\/wp\/v2\/tags?post=1879"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}